2Nicodemo AC.An open label,multicenter,non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia:a Brazilian study in five centers.Braz J Infect Dis,2003,7(1):62-8. 被引量：1
3[3]Lober S,Ziege S, Rau M,et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium[J ]. Antimicrob Agents Chemother, 1999, 43(5): 1 067. 被引量：1
4[4]Lutsar I,Friedland IR,Wubbel L, et al. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis[J]. Antimicrob Agents Chemother, 1998, 42 (10):2 650. 被引量：1
5[5]Gajjar DA, Lacreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men[J]. Pharmacotherapy, 2000, 20(6 Pt 2): 49. 被引量：1
6[6]Lacreta FP, Kollia GD, Duncan G, et al. Age and gender effects on the pharmacokinetics of gatifloxacin[J ]. Pharmacotherapy, 2000, 20(6 Pt 2) :67. 被引量：1
7[7]Grasela DM, Lacreta FP, Kollia GD, et al. Open-label,nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers[J ]. Pharmacotherapy, 2000, 20(3): 330. 被引量：1
8[8]Lu T,Zhao X,Drlica K.Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8methoxy group[J ]. Antimicrob Agents Chemother, 1999,43(12):2 969. 被引量：1
9[9]Fukuda H, Hiramatsu K.Primary targets of fluoroquinolones in streptococcus pneumoniae[J]. Antimicrob Agents Chemother, 1999, 43(2): 410. 被引量：1
10[10]Yamamoto T, Kusajima H, Hosaka M, et al. Uptake and intracellular activity of AM- 1155 in phagocytic cells[J].Antimicrob Agents Chemother, 1996, 40(12): 2 756. 被引量：1
